2Cole SPC, Bhardwa JG, Gerlach JH, et al. Overexpression of transporter gene in a mulfidrug-resistant human lung cancer cell line.Science, 1992, 258 : 1650-1654. 被引量：1
3Bradshaw DM, Arceci BJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol, 1998,16 : 3674 -3690. 被引量：1
4Breunlnger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells coders muhidrug resistance associated with increased drug etllux and altered intracellular drug distribution. Cancer Res, 1995, 55:5342-5347. 被引量：1
5Hipfner DR, Deeley RG, Coloe SP. Structural, mechanistic and clinical aspects of MRPI. Biochim Biophys Acta, 1999, 1461:359-376. 被引量：1
6Sczakiel G. The design of antisense RNA. Antisense Nucleic Acid Drug Dev, 1997, 7:439-444. 被引量：1
7Richert ND, Aldwin L, Nitesci D, et al. Stability and covalent modification of P-glycoprotein in multidrug resistance KB cells.Biochemistry, 1988, 27:760. 被引量：1
8Christiane N, Axel P, Alexandra S. Modulation of classical multidrug resistance phenotype by RNA interference [ J ]. FEBS Letters,2003,545 (2) :145 - 150. 被引量：1
9Pakunlu RI,Wang Y,Tsao W,et al. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense : novel multicomponent delivery system [ J ]. Cancer Research, 2004, 64 (17) :6214 - 6223. 被引量：1
10De Pauw R, van Meerbeeck JP. Neoadjuvant chemotherapy in the treatment of non small-cell lung cancer [ J ]. Curt Opin Oncol, 2007, 19(2) :92 -97. 被引量：1
